← All trials
NCT06525389
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 6, 2025
- Primary completion
- Jan 6, 2030
- Completion date
- Jan 6, 2032
- First posted
- Jul 29, 2024
- Last posted
- Aug 19, 2024
- Enrollment
- 428
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Bach Mai HospitalCollaborator
- Tropical Diseases Hospital, Ho Chi Minh CityCollaborator
- Pham Ngoc Thach University of MedicineCollaborator
- Chiangmai UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Gilead SciencesCollaborator
- Maharat Nakhon Ratchasima HospitalCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Duke UniversityOfficial
- National Hospital for Tropical Diseases, Hanoi, VietnamCollaborator
- ViatrisCollaborator
- Shenzhen Third People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.